Global Amifampridine Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Amifampridine Market Research Report 2024
Amifampridine (pyridine-3,4-diamine, 3,4-diaminopyridine, 3,4-DAP) is used as a drug, predominantly in the treatment of a number of rare muscle diseases. The free base form of the drug has been used to treat congenital myasthenic syndromes and Lambert–Eaton myasthenic syndrome (LEMS) through compassionate use programs since the 1990s and was recommended as a first line treatment for LEMS in 2006, using ad hoc forms of the drug, since there was no marketed form
According to Mr Accuracy reports’s new survey, global Amifampridine market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Amifampridine market research.
Key manufacturers engaged in the Amifampridine industry include Jacobus Pharmaceutical, Unichem, BioMarin Pharmaceutical, Wockhardt, Glenmark Pharmaceuticals, Norris Pharm, BLD Pharm, Biosynth AG and Innovapharm, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Amifampridine were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Amifampridine market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Amifampridine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Jacobus Pharmaceutical
Unichem
BioMarin Pharmaceutical
Wockhardt
Glenmark Pharmaceuticals
Norris Pharm
BLD Pharm
Biosynth AG
Innovapharm
Founder Pharma
BroadPharm
CSNpharm
Merck
Segment by Type
Generic
Patent
Myasthenia Gravis
Potassium Channel Blocker
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Amifampridine report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Amifampridine market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Amifampridine market research.
Key manufacturers engaged in the Amifampridine industry include Jacobus Pharmaceutical, Unichem, BioMarin Pharmaceutical, Wockhardt, Glenmark Pharmaceuticals, Norris Pharm, BLD Pharm, Biosynth AG and Innovapharm, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Amifampridine were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Amifampridine market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Amifampridine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Jacobus Pharmaceutical
Unichem
BioMarin Pharmaceutical
Wockhardt
Glenmark Pharmaceuticals
Norris Pharm
BLD Pharm
Biosynth AG
Innovapharm
Founder Pharma
BroadPharm
CSNpharm
Merck
Segment by Type
Generic
Patent
Segment by Application
Myasthenia Gravis
Potassium Channel Blocker
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Amifampridine report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source